tiprankstipranks
CellaVision AB (CLVSF)
:CLVSF
Holding CLVSF?
Track your performance easily

CellaVision AB (CLVSF) Stock Price & Analysis

7 Followers

CLVSF Stock Chart & Stats


Options Prices

Currently, No data available
---

Ownership Overview

1.85%<0.01%97.94%
Insiders
<0.01% Other Institutional Investors
97.94% Public Companies and
Individual Investors

CLVSF FAQ

What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest stock price was $16.12 and its highest was $29.70 in the past 12 months.
    What is CellaVision AB’s market cap?
    CellaVision AB’s market cap is $468.32M.
      When is CellaVision AB’s upcoming earnings report date?
      CellaVision AB’s upcoming earnings report date is Feb 06, 2025 which is in 5 days.
        How were CellaVision AB’s earnings last quarter?
        CellaVision AB released its earnings results on Oct 24, 2024. The company reported $0.118 earnings per share for the quarter, missing the consensus estimate of $0.155 by -$0.036.
          Is CellaVision AB overvalued?
          According to Wall Street analysts CellaVision AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does CellaVision AB pay dividends?
            CellaVision AB pays a Annually dividend of $0.204 which represents an annual dividend yield of 1.07%. See more information on CellaVision AB dividends here
              What is CellaVision AB’s EPS estimate?
              CellaVision AB’s EPS estimate is 0.17.
                How many shares outstanding does CellaVision AB have?
                CellaVision AB has 23,851,547 shares outstanding.
                  What happened to CellaVision AB’s price movement after its last earnings report?
                  CellaVision AB reported an EPS of $0.118 in its last earnings report, missing expectations of $0.155. Following the earnings report the stock price went down -0.228%.
                    Which hedge fund is a major shareholder of CellaVision AB?
                    Currently, no hedge funds are holding shares in CLVSF
                    ---

                    Company Description

                    CellaVision AB

                    CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced rbc application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China and Japan. The company derives the majority of its revenue from the sale of analyzers.
                    ---

                    CLVSF Earnings Call

                    Q3 2024
                    0:00 / 0:00
                    Earnings Call Sentiment|Neutral
                    The call reflected a mix of strong growth in EMEA and positive strategic developments, offset by challenges in the Americas and APAC regions, and increased expenses. Despite some regional and financial fluctuations, the company's strategic initiatives and growth in core areas provide a balanced outlook.Read More>
                    ---
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Altamira Therapeutics
                    Accelerate Diagnostics
                    NovoCure
                    Hologic
                    Illumina
                    Amgen
                    Popular Stocks
                    ---
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis